WCPD Lima-Preliminary Program Web

Start time 2019-10-15
Finished Time 2019-10-17
Address LIMA, PERU
Content

 

Web: www.wcpdcongress.com

WEDNESDAY
Time
08:00-08:30 Welcome Remarks
08:30-09:10 Plenary session: Cardiovascular disease prevention in people at high risk of diabetes: We need long-term efficacy trials in prediabetes – Simon Griffin/Rury Holman, UK
09:10-09:50 Plenary session: Technologies supporting diabetes prediction and prevention
09:50-10:10 Coffee Break: Exhibition hall/posters

 

Time Room 1 Room 2 Room 3
10:10-13:00 SESSION 1

-Type 1 DM

  • Changing the natural history of type 1 diabetes – Paolo Pozzilli, Italy
  • Case diagnosis at different ages. Implication for prevention – Dana Dabalea, USA
  • Current Primary and secondary trials for T1D prevention: an update – Annette Ziegler, Germany
  • Novel therapies for treating T1D and preventing beta-cell failure – David Leslie, UK
SESSION 2

Gestational Diabetes

A window for diabetes prevention

  • The public health impact of adapting the IADPSG criteria for the diagnosis of gestational diabetes mellitus.
  • Management of gestational diabetes: nutritional and pharmacological therapy
  • Prevention of gestational diabetes in different populations; focus on low-middle income countries
SESSION 3

Obesity a major risk factor for type 2 diabetes:

  • Obesity in Childhood and adolescence – NN, Mexico
  • Relative fat mass, a new method to define obesity – Orison O. Woolcott, USA
  • Effects of weight reduction on type 2 diabetes prevention – Jaana Lindstom, Finland
  • Bariatric and Metabolic Surgery for prevention of type 2 diabetes – Lena Carlsson, Sweden
13:00-14:30 Lunch Symposium 1

SANOFI

CVD outcome trials in T2D

Lunch Symposium 2

MSD

T2D a CVD. Update safety trials

Lunch Symposium 3

BI-Lilly

DPPIV-i

Insulin Glargine

14:30-15:30 SESSION 4

Hypertension and diabetes:

  • Hypertension, diabetes and kidney impairment: The three killer connection – Ehud Grossman, Israel
  • New guidelines for treating hypertension in diabetes – Giuseppe Mancia, Italy
  • Lessons from the SPRINT trial – William Cushman
  • Should threshold for starting treatment for mild hypertension in PD be lowered (NICE, ESCEASD recommendations)? – Amanda Adler, UK
  • Hypertension and the kidney in Prediabetics and early diabetics Patricio López Jaramillo, Colombia
SESSION 5

New strategies in the prevention of type 2 diabetes:

  • Followup of diabetes prevention trials – Jaakko Tuomilehto, Finland
  • Circardian rythm and prevention of diabetes and metabolic síndrome – Paul Zimmet, Australia
  • Moderate ketogenic diet intervention to prevent diabetes – Fred Brouns, Netherlands
  • Early prevention of macro and microvascular complications – Rafael Gabriel
SESSION 6

Early detection and treatment of diabetic specific complications (microvascular):

  • New technologies in the assessment and treatment of retinopathy NN
  • Developments in the pathophysiology and treatment of neuropathy – Solomon Tesfaye, UK
  • Renal impairment – Peter Rossing, Denmark
  • Cardiovascular Autonomic neuropathy – Paul Valensi, France
15:30-16:00 Coffee break

Exhibition hall/posters

Visit

Coffee break

Exhibition hall /posters visit

Coffee break

Exhibition hall /posters visit

16:00-18:00 SESSION 7

Physical Activity

  • Prevention of diabetes by physical activity – Jean Pierre Depres, Canada
  • Is fit/fat phenotype healthy? Susumu S. Sawada, Japan
  • Prevention of gestational diabetes by physical activity –Stephanie May Ruchat , Canada
  • Effects of physical activity on cardiometabolic health in the elderly
SESSION 8

Lipids atherosclerosis – joint with International Atherosclerosis Society

  • Dyslipidemia in prediabetes and its effects on progression to diabetes – Fotios Barkas, Greece
  • Statins and diabetes: Current status – Jennifer Robinson, USA
  • PCSK9 antibody therapy in diabetes and prediabetes – Raul Santos, Brazil
  • International Guidelines for lipid management in diabetes and prediabetes – Zeljko Reiner, Croatia
SESSION 9

Prevention of Diabetes complications and associated comorbidities:

  • Traditional and nontraditional complications of diabetes – Jaime Miranda, Peru
  • Cardiovascular Risk Assessment – Francesco Cosentino, Sweden
  • Update on cardiovascular outcome trials
  • Cognition and Alzheimer’s Disease in diabetes and prediabetes – Michael Brainin, Austria
  • Diabetes and infection
  • Peripheral artery disease
18:00-18:45 MENARINI AWARD LECTURE
18:45-20:00 RECEPTION AT POSTERS

 

THURSDAY National Peruvian Diabetes Day (in Spanish)
Time
08:30-09:10 Plenary Session: Genetics-omics: Prediction of type 2 diabetes using genetic markers profiling – Jose Florez, USA Conference: TBD by local organizers

Diabetes en el Perú

09:10-09:50 Plenary Session: Prevention of Type 2 Diabetes in low – / middle – income countries (IDF/GACD/WHO-PAHO) TBD by local organizers
09:50-10:10 Coffee Break: Exhibition hall/posters Coffee Break: Exhibition hall/posters

Time Room 1 Room 2 Room 3
10:10-13:00 SESSION 10

Global health and Diabetes

  • Diabetes prevention in US Native Americans Luohua Jiang, USA
  • Diabetes in indigenous populations in Latin America NN
  • Global actions, Health policy/Health Diplomacy – World Bank
  • What can we learn about prevention from tobacco control? – Mervi Hará, Finland
SESSION 11

Risk Scores for T2D:

  • -Existing effective risk scores (review) – Simon Griffin, UK
  • Transculturization and validation of diabetes risk scores – Stephen Colaguiri, Australia
  • Improvement of risk scores (1h post load OGTT) – Michael Bergman, USA
  • Genetic risk scores – Miriam Udler, USA
SESSION 12

Novel dietary approaches for prevention of type 2 diabetes:

  • Sugar Sweetened Beverages and Risk of Metabolic Syndrome and Type 2 Diabetes – Vasanti Malik, USA
  • Low carb, low fat, liquid diet – Mike Lean, UK
  • Mediterranean diet, Baltic diet what is the best diet?
  • Coffee, chocolate and other dietary supplements…
  • Brain reactivity to food cues – PREVIEW trial – Mathijs Drummen, Netherlands
TBD by local organizers. MEDTRONIC?

Variabilidad de la Glucosa e Hipoglicemia. Un riesgo prevenible:

  • Clasificación de la hipoglicemia
  • Mejora del conocimiento de la hipoglicemia
  • Miedo a la hipoglicemia
13:00-14:30 Lunch Symposium 4

NOVO NORDISK:

Role of GLP-1 agonist in the prevention of T2D, CVD and weight loss

Lunch 5

PATIA: Genomics (Diabetes PREVENT)

Lunch 6

ASTRA-ZENECA

OPEN

Symposio Almuerzo

TBD by local organizers

Insulino terapia?

BAGÓ? BRAUN?, HERSIL? WORWAG? Roemmers? TECNOFARMA?

14:30-15:30 SESSION 13

Fatty Liver and T2D

  • -NAFLD in the context of prediabetes and diabetes states
  • -The Liver as a target organ for understanding development of diabetes
  • -The gut-liver axis connection in T2D
SESSION 14

SUMMIT on CVD prevention in prediabetes

  • Lifestyle and CVD prevention – Guangwei Li, China
  • Drugs in CVD prevention:
  • Antidiabetics
  • Lipid lowering
  • Antihypertensives
  • Aspirin
  • Polypill for diabetes?
  • Multifactorial approach for CVD and type 2 diabetes prevention in prediabetes – Lars Ryden, Sweden
SESSION 15

eHealth and Diabetes Prevention:

  • Smartphones for promotion of healthy lifestyles – Ambady Ramachandran, India
  • Prevention of Metabolic Syndrome by Telephone-Delivered Lifestyle Intervention in a Real-World Setting- Naoki Sakane, Japan
  • Linking Big data for diabetes prevention – NN
  • Review of Apps for Diabetes prevention in the market – NN
Manejo actual de la prediabetes y diabetes tipo2 según las guías clínicas basadas en la evidencia:

-estilos de vida

  • metformina
  • otros (inhibidores DPPIV, inhibidores de SGLT2, agonistas del receptor GLP-1, combinación de fármacos e Insulinas en DT2)
15:30-16:00 Coffee break

Exhibition hall/posters

Coffee break

Exhibition hall/posters

Coffee break

Exhibition hall/posters

TBD by local organizers. Simposio ALAD/Sociedad Peruana de Diabetes:

Experiencias en prevención de DT2 en Perú y LA

16:00-18:00 SESSION 16

Kidney disease in T2D

  • Early renal function abnormalities and albuminuria in prediabetes implication for prevention of diabetes
  • Renal protective effect of antidiabetic and antihypertensive drugs
SESSION 17

Psycho-social factors in T2D:

  • Social deprivation, migration and diabetes risk – Jaime Miranda, Peru
  • Diabetes and depression
  • Quality of life in people at high risk of type 2 diabetes
  • Antipsychotic drugs and diabetes/obesity risk
  • Importance of social support in diabetes prevention
SESSION 18

National Programs

(implementation/Scaling-up)

Lessons from implementation of T2D prevention programs in real world: experiences around the world:

  • -North America – Ann Albgright, USA
  • – Europe – Kamlesh Khunti, UK
  • -Latin America – Tania Acosta, Colombia
  • -Asia-Pacific – Juliana Chan, Hong Kong
  • -Africa – Sudhirsen Kowlessur, Mauritius
  • – Middle East – Mahmoud Ibrahim, USA/Egypt

LUNCH SYMPOSIUM (Proposal)

  • Training (coaching) in Lifestyle modification:
  • -Role of lay persons in diabetes prevention
  • -Role of educators
  • -Patient´s empowering
TBD by local organizers

 

FRIDAY
Time
09:00-09:40 Plenary Session: Economics: The Cost Effectiveness of Diabetes Prevention – Samantha Roberts, UK
09:40-10:10 Coffee Break Exhibition hall/posters
Time Room Room Room
10:10-13:00 SESSION 19

Social and Enviromental factors & interventions in Diabetes Prevention

  • Social and environmental risk factors .
  • Climate change, urban health policy and diabetes – Jean Claude Mbanya, Cameroon
  • Noise and diabetes
  • Air Polllution and diabetes
  • Urban policy health and diabetes
  • Social Networks and prevention of T2D
  • Cities Changing Diabetes Mexico
SESSION 20

Prediabetes and T2D in specific group populations: women, youth and the elderly.

  • Prevention of the metabolic syndrome in adolescence and youth – Timo Lakka, Finland
  • Gender and age related biases in diabetes prevention and care – Harraiter J, Austria
  • Contraception and hormone replacement therapy Franck Mauvais Jarvis, USA
  • Is it time for gender and age specific guidelines in diabetes prevention and care? Alexandra Kautzky Willer, Austria
SESSION 21

Pharmacologic intervention in prediabetes

  • Metformin – someone from DPP DPPIVi – Pablo Aschner, Colombia
  • SGLT2 – Marit Jorgensen, Denmark
  • GLP1 – Carel le Roux, Ireland
  • αglucosidase inhibitors – Eberhard Standl, Germany
13:00-14:30 Lunch symposium 7

MONDELEZ INT.

Snacking and ObesityT2D

Lunch symposium 8

UNILEVER

OPEN

Lunch symposium 9

MERCK

OPEN

 

FRIDAY – CUZCO SYMPOSIUM
Time
09:00-09:45 Opening lecture TBD
09.45-10:45 Debate

TBD

10:45-11:00 Coffee break
11:00-12:45 Round table, TBD
12:45-13:00 Concluding remarks
13:00 Lunch and departure

 

International speakers (to be confirmed)
EUROPE

Nick Wareham

Philip Home

Andrew Boulton

Rury Holman

Itamar Raz

Michael Roden

Jaana Lindstrom

Lars Ryden

Francisco Cosentino

Michael Brainin

Alain Golay

Peter Schwarz

Bjarne JuulJensen Steno

Oliver Schnell, Germany

Antonio Ceriello, Spain

Bjørn Åsvold

Konstantoinos Makrilakis, Greece

Paul Valensi

Michel Marre, France

Kamlesh Khunti, UK

John Nolan, Ireland

Joao Filipe Raposo, Portugal

Edith Feskens

Jose Boavida, Portugal

David Leslie

Manuel SerranoRios , Spain

WDF

Leif Fenger Jensen

Obesity

Victor Saavedra Gajardo, Chile

Donna Ryan, USA

John Wilding, UK

International Society of Behavioral Nutrition and Physical Activity (ISBNPA)

António Labisa Palmeira, Portugal, Executive Director

European Association of Preventive Cardiology

Paul Dendale, Belgium, President

AHA Council on Lifestyle and Cardiometabolic Health

Penny M. KrisEtherton, Chair

LATIN AMERICA

One member from each country

Carlos Slim Foundation

President ALAD

Tania Acosta

Jose Esteban Costa Gil

AFRICA

Kaushik Ramaya, Tanzania

JeanClaude Mbanya, Cameron

Naomi Lewitt, South Afric

Silver Bahendeka, Uganda

NORTH AMERICA (USA, Canada and Mexico)

Ann Albright

Michael Bergman

Venkat Narayan

Noel Barengo

Enrique Caballero

David Nathan

Ralph DeFronzo

JeanPierre Despres

Lawrence Leiter

Marian Rewers

Jose Florez

Seema Nagpal

Beatriz Rodriguez

Clicerio GonzálezVillalpando

Jose Augustin Mesa

David Matthews, President EASD

William Cefalu, Scientific Director ADA

Jessica Yeh, Chair, Public Health and Epidemiology Interest Group

MENA countries

Monira Al Arouj, Kuwait

Abdul Razzak Madani, Dubai

CHINA

Guangwei Li

Jianping Weng, President, Chinese Diabetes Society

JAPAN

Naoki Sakane

Naoko Tajima

Japan Diabetes Society

Takashi Kadowaki, Chairman of the Board of Directors

INDIA

Banshi Saboo

Charles Antonypillai, Sri Lanka

AUSTRALIA

James Dunbar

Stephen Colagiuri

Paul Zimmet

Brian Oldenburg

Alex Brown

Glynis Ross, President, Australian Diabetes Society

HYPERTENSION

Michael J. Cryer

LIPIDS

Raul Santos, Brazil, President of International Atherosclerosis Society

KIDNEY

Mark Cooper, Melbourne

EYES

Tien Y. Wong, Singapore